Ezt az oldalt automatikusan lefordították, és a fordítás pontossága nem garantált. Kérjük, olvassa el a angol verzió forrásszöveghez.

REducing Systemic Inflammation With LOw-dose Colchicine to ImproVE Cardiovascular Calcification in Chronic Kidney Disease: A Pilot Randomized Open-Label Trial (RESOLVE-CKD)

2026. október 30. frissítette: Jing Chen, University of Texas Southwestern Medical Center

REducing Systemic Inflammation With LOw-dose Colchicine to ImproVE Cardiovascular Calcification in Chronic Kidney Disease: A Pilot Randomized Open-Label Trial (RESOLVE-CKD Trial)

This pilot randomized, open-label, outcome blinded clinical trial is to evaluate the preliminary effects of low-dose Colchicine (LoDoCo) on coronary artery calcification (CAC) progression in adults with chronic kidney disease (CKD) and existing coronary artery calcification. Sixty participants will be randomized 1:1 to received LoDoCo plus usual care or usual care lone and followed for 24 months.

The primary objective is to evaluate the effect of LoDoCo on CAC progression measured by ECG-gates noncontrast cardiac computed tomography (CT). Exploratory outcomes include valvular calcification, bone mineral density, inflammatory, vascular, and miner-bone biomarkers, cognitive function, Alzheimer's disease biomarkers, peripheral arterial disease measures, kidney biomarkers, and participant-reported measures of treatment acceptability, adherence, and adverse effects.

A tanulmány áttekintése

Részletes leírás

The investigators will conduct a randomized, open-label, outcome-blinded, clinical trial in 60 adults with chronic kidney disease (CKD) and existing coronary artery calcification (CAC) Agatston scores of ≥100-1000. Participants will be randomized 1:1 to receive low-dose Colchicine (LoDoCo) plus usual care or usual care alone for 24 months.

The primary objective is to evaluate the effect of LoDoCo on CAC progression over 24 months. CAC will be assessed by ECG-gated noncontrast cardiac computed tomography (CT). Outcomes will include Agatston score and calcium volume. The study will estimate variance, baseline-to-follow-up correlations, and other parameters needed to inform future sample size, treatment duration, and endpoint selection.

Exploratory objectives include evaluating the effects of LoDoCo on aortic valve and mitral annular calcification, CT-derived vertebral bone mineral density, inflammatory biomarkers, vascular calcification biomarkers, and miner-bone metabolism biomarkers. Additional exploratory analyses will examine cognitive function, Alzheimer's disease biomarkers, peripheral arterial disease measures including ankle-brachial index (ABI) and toe-brachial index (TBI), and kidney outcomes including albumin-creatine ratio (uACR) and estimated glomerular filtration rate (eGFR).

Participant experience with LoDoCo will also be evaluated through assessment of treatment acceptability, adherence, adverse effects, and barriers and facilitators to study participation and retention.

Participants will be followed at baseline, 6 months, 12 months, 18 months, and 24 months for data collection. Participants assigned to the intervention group will undergo additional safety monitoring, including laboratory assessments, throughout the study period.

Tanulmány típusa

Beavatkozó

Beiratkozás (Becsült)

60

Fázis

  • 2. fázis

Kapcsolatok és helyek

Ez a rész a vizsgálatot végzők elérhetőségeit, valamint a vizsgálat lefolytatásának helyére vonatkozó információkat tartalmazza.

Tanulmányi kapcsolat

Tanulmányozza a kapcsolattartók biztonsági mentését

Tanulmányi helyek

Részvételi kritériumok

A kutatók olyan embereket keresnek, akik megfelelnek egy bizonyos leírásnak, az úgynevezett jogosultsági kritériumoknak. Néhány példa ezekre a kritériumokra a személy általános egészségi állapota vagy a korábbi kezelések.

Jogosultsági kritériumok

Tanulmányozható életkorok

30 év (Felnőtt, Idősebb felnőtt)

Egészséges önkénteseket fogad

Nem

Tanulmányozható nemek

Összes

Leírás

Inclusion Criteria:

  • Men and women aged 30-<70 years of all race/ethnicity groups
  • Chronic kidney disease (CKD) stage 3 (estimated glomerular filtration rate (eGFR) 30 to <60 ml/min/1.73m2) or eGFR ≥60 and Urine albumin-to-creatinine ratio (uACR) ≥ 30 mg/g
  • Cardiac artery calcification (CAC) Agatston score ≥100-1000
  • Ability to provide informed consent.

Exclusion Criteria:

  • Current Colchicine therapy
  • Hepatic disease
  • Established peripheral arterial disease (PAD) defined by self-report or ICD-10 codes
  • Congestive heart failure classified as New York Heart Association (NYHA) Functional class III or IV
  • Uncontrolled atrial fibrillation with resting heart rate > 100 beats/min
  • Dementia defined by self-report or ICD-10 codes (F01-F03)
  • Alzheimer's disease defined by self-report or ICD-10 codes (G30)
  • Any clinically active diagnosed infection requiring systemic antimicrobial therapy, positive microbiologic evidence of infection, or infection-related hospitalization within 30 days prior to study enrollment.
  • Immunosuppression, including the use of immunosuppressive medications
  • Current use of chemotherapy drugs or active cancer
  • Pregnancy/breastfeeding
  • Hospitalized within the past 6 months
  • Allergic/intolerance to colchicine
  • Use of P-glycoprotein (p-gp) inhibitor (such as Verapamil, Quinidine, Amiodarone, Ritonavir, Lopinavir/ritonavir, Saquinavir, Nelfinavir)
  • Use of strong cytochrome P450 3A4 (CYP3A4) inhibitors (such as Ketoconazole, Itraconazole, Posaconazole, Voriconazole, Clarithromycin, Erythromycin)
  • Human immunodeficiency virus (HIV) infection
  • Gout attack ≥ 1 time per year
  • Severe anemia (hemoglobin < 8 g/dl for women and < 9 g/dl for men)
  • eGFR <30 ml/min/1.73m2
  • White blood cell count (WBC) <3.0 x10^9/L
  • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 x Upper Limit of Normal (ULN)
  • Total bilirubin >2 x ULN
  • Glucose >300mg/dL
  • Uses recreational drugs
  • Participant in other conflict clinical trial
  • Unable to complete the study measurements
  • Unable to undergo to computed tomography (CT)
  • Unsafe to participate in this study per investigator's judgement
  • Unable to read and speak English or Spanish

Tanulási terv

Ez a rész a vizsgálati terv részleteit tartalmazza, beleértve a vizsgálat megtervezését és a vizsgálat mérését.

Hogyan készül a tanulmány?

Tervezési részletek

  • Elsődleges cél: Kezelés
  • Kiosztás: Véletlenszerűsített
  • Beavatkozó modell: Párhuzamos hozzárendelés
  • Maszkolás: Egyetlen

Fegyverek és beavatkozások

Résztvevő csoport / kar
Beavatkozás / kezelés
Aktív összehasonlító: Low-Dose Colchicine (LoDoCo)

Participants will receive low-dose Colchicine (LoDoCo) in addition to usual care.

Intervention group will receive LoDoCo (Colchicine 0.5mg), oral, once daily.

Más nevek:
  • LoDoCo

Participants will receive usual care according to standard clinical practice and treating physician discretion.

Aktív összehasonlító: Usual Care

Participants will receive usual care alone.

Participants will receive usual care according to standard clinical practice and treating physician discretion.

Mit mér a tanulmány?

Elsődleges eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
Change in Coronary Artery Calcification Agatston Scores
Időkeret: Baseline, 12 months, 24 months

Agatston scores (Agatston units) will be measured by ECG-gated non-contrast cardiac computed tomography (CCT) scans following standard cardiac imaging protocols. Coronary artery calcification will be quantified using the Coronary Artery Calcium (CAC) Agatston Score. Scores range from 0 Agatston units (no detectable coronary calcification), 1-99 Agatston units (mild calcification), 100-399 Agatston units (moderate calcification), and ≥400 Agatston units (severe calcification, high atherosclerotic burden). Higher scores indicate greater coronary artery calcification and are associated with worse outcomes.

Baseline, 12 months, 24 months
Change in Coronary Artery Calcification Volume Scores
Időkeret: Baseline, 12 months, 24 months

Change in Coronary Artery Calcification volume (mm3) will be measured by ECG-gates non-contrast cardiac computed tomography (CCT) scans following standard cardiac imaging protocols.

Baseline, 12 months, 24 months

Egyéb eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
Exploratory: Change in Aortic Valve Calcification Agatston Scores
Időkeret: Baseline, 12 months, 24 months

Agatston scores (Agatston units) will be measured by ECG-gated non-contrast cardiac computed tomography (CCT) scans following standard cardiac imaging protocols. Aortic valve calcification will be quantified using the Agatston Scoring method applied to calcified lesions of the aortic valve. Scores range from 0 Agatston units (no detectable coronary calcification), 1-99 Agatston units (mild calcification), 100-399 Agatston units (moderate calcification), and ≥400 Agatston units (severe calcification, high atherosclerotic burden). Higher scores indicate greater coronary artery calcification and are associated with worse outcomes.

Baseline, 12 months, 24 months
Exploratory: Change in Aortic Valve Calcification Volume Scores
Időkeret: Baseline, 12 months, 24 months

Change in Aortic Valve Calcification volume (mm3) will be measured by ECG-gated non-contrast cardiac computed tomography (CCT) scans following standard cardiac imaging protocols.

Baseline, 12 months, 24 months
Exploratory: Change in Mitral Annular Calcification Agatston Scores
Időkeret: Baseline, 12 months, 24 months

Agatston scores (Agatston units) will be measured by ECG-gated non-contrast cardiac computed tomography (CCT) scans following standard cardiac imaging protocols. Mitral annular calcification will be quantified using the Agatston Scoring method applied to calcified lesions of the mitral valve annulus. Scores range from 0 Agatston units (no detectable coronary calcification), 1-99 Agatston units (mild calcification), 100-399 Agatston units (moderate calcification), and ≥400 Agatston units (severe calcification, high atherosclerotic burden). Higher scores indicate greater coronary artery calcification and are associated with worse outcomes.

Baseline, 12 months, 24 months
Exploratory: Change in Mitral Annular Calcification Volume Scores
Időkeret: Baseline, 12 months, 24 months

Change in Mitral Annular Calcification volume (mm3) will be measured by ECG-gates non-contrast cardiac computed tomography (CCT) scans following standard cardiac imaging protocols.

Baseline, 12 months, 24 months
Exploratory: Change in Vertebral Bone Mineral Density (BMD)
Időkeret: Baseline, 12 months, 24 months

Change in vertebral BMD (mg/cm³) will be measured from ECG-gated non-contrast computer tomography (CT) using validated CT-based densitometry methods. BMD will be quantified within the vertebral bodies. Vertebral MBD values range from <80mg/cm³ (very low), 80-120mg/cm³ (low), and >120 mg/cm³ (normal). Lower TBI values are associated with worse outcomes.

Baseline, 12 months, 24 months
Exploratory: Change in C-Reactive Protein (CRP) Levels
Időkeret: Baseline, 12 months, 24 months

Circulating CRP (mg/L) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Interleukin-1 beta (IL-1β) Levels
Időkeret: Baseline, 12 months, 24 months

Circulating IL-1β levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Interleukin-6 (IL-6) Levels
Időkeret: Baseline, 12 months, 18 months

Circulating IL-6 levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 18 months
Exploratory: Change in Interleukin-18 (IL-18) Levels
Időkeret: Baseline, 12 months, 24 months

Circulating IL-18 levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Tumor Necrosis Factor alpha
Időkeret: Baseline, 12 months, 24 months

Circulating TNF-a levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Interleukin-17 (IL-17) Levels
Időkeret: Baseline, 12 months, 24 months

Circulating IL-17 levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Monocyte Chemoattractant Protein-1 (MCP-1) levels
Időkeret: Baseline, 12 months, 24 months

Circulating MCP-1 levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Serum Klotho Levels
Időkeret: Baseline, 12 months, 24 months

Circulating klotho levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Fetuin A Levels
Időkeret: Baseline, 12 months, 24 months

Circulating fetuin A levels (ng/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Osteopontin Levels
Időkeret: Baseline, 12 months, 24 months

Circulating osteopontin levels (ng/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Bone Morphogenetic Protein-2 (BMP-2) Levels
Időkeret: Baseline, 12 months, 24 months

Circulating BMP-2 levels (ng/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Bone Morphogenetic Protein-4 (BMP-4) Levels
Időkeret: Baseline, 12 months, 24 months

Circulating BMP-4 levels (ng/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Bone Morphogenetic Protein-7 (BMP-7) Levels
Időkeret: Baseline, 12 months, 24 months

Circulating BMP-7 levels (ng/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Serum Phosphate levels
Időkeret: Baseline, 12 months, 24 months

Circulating serum phosphate levels (mg/dL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Serum Calcium Levels
Időkeret: Baseline, 12 months, 24 months

Circulating serum calcium levels (mg/dL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Parathyroid Hormone (PTH) levels
Időkeret: Baseline, 12 months, 24 months

Circulating PTH levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Bone-Specific Alkaline Phosphatase (BSAP) Levels
Időkeret: Baseline, 12 months, 24 months

Circulating serum BSAP levels (ug/L) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Fibroblast Growth Factor 23 (FGF23) Levels
Időkeret: Baseline, 12 months, 24 months

Circulating FGF23 levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Wnt Inhibitory Factor-1 Levels
Időkeret: Baseline, 12 months, 24 months

Circulating Wnt Inhibitory Factor-1 (pg/dL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Intact N-Terminal Propeptide of Type I Procollagen (P1NP) Levels
Időkeret: Baseline, 12 months, 24 months

Circulating P1NP levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Sclerostin Levels
Időkeret: Baseline, 12 months, 24 months

Circulating sclerostin levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Tartrate-Resistant Acid Phosphatase 5b (TRAP-5b) Levels
Időkeret: Baseline, 12 months, 24 months

Circulating TRAP-5b levels (U/L) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in National Institutes of Health (NIH) Toolbox Fluid Cognition Composite Standard Score
Időkeret: Baseline, 12 months, 24 months

The NIH Toolbox Fluid Cognition Composite score assesses cognitive functions involved in processing and responding to new information, including attention, executive function, episodic memory, processing speed, and working memory. The age-adjusted Fluid Cognition Composite Standard Score is derived from participant performance on NIH Toolbox cognitive assessments and calculated according to NIH Toolbox scoring procedures. Scores are reported as standard scores without physical units, with a normative mean of 100 and standard deviation of 15. Scores of 70 or lower indicate significant impairment, scores around 85 are below average, scores around 100 are average, scores around 115 are above average, and scores around 130 are superior. Higher scores indicate better cognitive performance.

Baseline, 12 months, 24 months
Exploratory: Change in Executive Function
Időkeret: Baseline, 12 months, 24 months

Executive function will be assessed using the NIH Toolbox Dimensional Change Card Sort Test. Change in the age-adjusted standard score will be derived from participant performance and calculated according to NIH Toolbox scoring procedures. Scores are reported as standard scores without physical units, with a normative mean of 100 and standard deviation of 15. Higher scores indicating better executive functioning.

Baseline, 12 months, 24 months
Exploratory: Change in Attention/Inhibitory Control
Időkeret: Baseline, 12 months, 24 months

Attention and inhibitory control will be assessed using the NIH Toolbox Flanker Inhibitory Control Test. Change in the age-adjusted standard score will be derived from participant performance and calculated according to NIH Toolbox scoring procedures. Scores are reported as standard scores without physical units, with a normative mean of 100 and standard deviation of 15. Higher scores indicating better attention and inhibitory control.

Baseline, 12 months, 24 months
Exploratory: Change in Processing Speed
Időkeret: Baseline, 12 months, 24 months

Processing speed will be assessed using the NIH Toolbox Pattern Comparison Processing Speed test. Change in the age-adjusted standard score will be derived from participant performance and calculated according to NIH Toolbox scoring procedures. Scores are reported as standard scores without physical units, with a normative mean of 100 and standard deviation of 15. Higher scores indicating better processing speed.

Baseline, 12 months, 24 months
Exploratory: Change in Working Memory
Időkeret: Baseline, 12 months, 24 months

Working memory will be assessed using the NIH Toolbox List Sorting Working Memory Test. Change in the age-adjusted standard score will be derived from participant performance and calculated according to NIH Toolbox scoring procedures. Scores are reported as standard scores without physical units, with a normative mean of 100 and standard deviation of 15. Higher scores indicating better working memory.

Baseline, 12 months, 24 months
Exploratory: Change in Episodic Memory
Időkeret: Baseline, 12 months, 24 months

Episodic memory will be assessed using the NIH Toolbox Picture Sequence Memory Test. Change in the age-adjusted standard score will be derived from participant performance and calculated according to NIH Toolbox scoring procedures. Scores are reported as standard scores without physical units, with a normative mean of 100 and standard deviation of 15. Higher scores indicating better episodic memory.

Baseline, 12 months, 24 months
Exploratory: Change in Language/Vocabulary
Időkeret: Baseline, 12 months, 24 months

Language/Vocabulary will be assessed using the NIH Toolbox Picture Vocabulary Test and Oral Reading Recognition tests. Change in the age-adjusted standard score will be derived from participant performance and calculated according to NIH Toolbox scoring procedures. Scores are reported as standard scores without physical units, with a normative mean of 100 and standard deviation of 15. Higher scores indicating better language ability.

Baseline, 12 months, 24 months
Exploratory: Change in Southwestern Assessment of Processing Speed (SWAPS) Score
Időkeret: Baseline, 12 months, 24 months

The SWAPS will be used to assess processing speed. Change in the normalized T-score will be derived from participant performance and calculated according to SWAPS scoring procedures. Scores are reported as T-scores without physical units, with a normative mean of 50 and standard deviation of 10. Higher scores indicate better processing speed performance.

Baseline, 12 months, 24 months
Exploratory: Change in Texas Card Sorting Test (TCST) Score
Időkeret: Baseline, 12 months, 24 months

The TCST will be used to assess executive functioning, including cognitive flexibility and concept formation. Change in the normalized T-score will be derived from participant performance and calculated according to SWAPS scoring procedures. Scores are reported as T-scores without physical units, with a normative mean of 50 and standard deviation of 10. Higher scores indicate better executive functioning.

Baseline, 12 months, 24 months
Exploratory: Change in Phosphorylated tau 217 (p-tau217) levels
Időkeret: Baseline, 12 months, 24 months

Circulating p-tau217 levels (pg/mL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Amyloid-beta 42/40 ratio (Aβ42/40) Levels
Időkeret: Baseline, 12 months, 24 months

Circulating Aβ42 and Aβ40 levels (pg/mL) will be measured using standard clinical laboratory assays and the Aβ42/40 ratio calculated from these measurements and reported as a unitless ratio.

Baseline, 12 months, 24 months
Exploratory: Change in Ankle-Brachial Index (ABI)
Időkeret: Baseline, 12 months, 24 months

ABI will be measured using semi-automated validated device (simpleABI-600CL). ABI values range from ≤0.90 (Peripheral artery disease), 0.91-0.99 (borderline), 1.00-1.40 (normal).ABI values >1.40 indicate non-compressible arteries, suggestive of arterial stiffness or medial calcification. Both ABI values ≤0.90 and >1.40 are associated with worse outcomes.

Baseline, 12 months, 24 months
Exploratory: Change in Toe-Brachial Index (TBI)
Időkeret: Baseline, 12 months, 24 months

TBI will be measured using semi-automated validated device (simpleABI-600CL). TBI values range from ≥0.70 (normal), 0.64-0.69 (borderline), and <0.40-0.50 (severe distal arterial disease/critical ischemia range). TBI values <0.70 is a commonly used threshold suggestive of peripheral artery disease. Lower TBI values are associated with worse outcomes.

Baseline, 12 months, 24 months
Exploratory: Change in Percentage of Participants with Ankle-Brachial Index (ABI) ≤0.9 or >1.4
Időkeret: Baseline, 12 months, 24 months

ABI will be measured using semi-automated validated device (simpleABI-600CL). The percentage (%) of participants with an ABI ≤0.9, indicative of peripheral arterial disease, or an ABI >1.4, indicative of non-compressible arteries suggestive of arterial stiffness or medial calcification will be determined. Higher percentages indicate a greater proportion of participants with abnormal ABI findings.

Baseline, 12 months, 24 months
Exploratory: Change in Urine Albumin-to-Creatine Ratio (uACR)
Időkeret: Baseline, 12 months, 24 months

Circulating urinary albumin and creatine levels (mg/dL) will be measured using standard clinical laboratory assays.

Baseline, 12 months, 24 months
Exploratory: Change in Estimated Glomerular Filtration Rate (eGFR)
Időkeret: Baseline, 12 months, 24 months

eGFR values (mL/min/1.73m2) will be calculated using the NKF-ASN CKD-Epi refit formula.

Baseline, 12 months, 24 months

Együttműködők és nyomozók

Itt találhatja meg a tanulmányban érintett személyeket és szervezeteket.

Nyomozók

  • Kutatásvezető: Jing Chen, MD, University of Texas

Publikációk és hasznos linkek

A vizsgálattal kapcsolatos információk beviteléért felelős személy önkéntesen bocsátja rendelkezésre ezeket a kiadványokat. Ezek bármiről szólhatnak, ami a tanulmányhoz kapcsolódik.

Általános kiadványok

Tanulmányi rekorddátumok

Ezek a dátumok nyomon követik a ClinicalTrials.gov webhelyre benyújtott vizsgálati rekordok és összefoglaló eredmények benyújtásának folyamatát. A vizsgálati feljegyzéseket és a jelentett eredményeket a Nemzeti Orvostudományi Könyvtár (NLM) felülvizsgálja, hogy megbizonyosodjon arról, hogy megfelelnek-e az adott minőség-ellenőrzési szabványoknak, mielőtt közzéteszik őket a nyilvános weboldalon.

Tanulmány főbb dátumok

Tanulmány kezdete (Becsült)

2026. október 30.

Elsődleges befejezés (Becsült)

2029. május 1.

A tanulmány befejezése (Becsült)

2029. május 1.

Tanulmányi regisztráció dátumai

Először benyújtva

2026. június 11.

Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak

2026. június 11.

Első közzététel (Tényleges)

2026. június 17.

Tanulmányi rekordok frissítései

Utolsó frissítés közzétéve (Tényleges)

2026. november 4.

Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak

2026. október 30.

Utolsó ellenőrzés

2026. október 1.

Több információ

A tanulmányhoz kapcsolódó kifejezések

Terv az egyéni résztvevői adatokhoz (IPD)

Tervezi megosztani az egyéni résztvevői adatokat (IPD)?

IGEN

IPD terv leírása

IRB approval is required before sharing IPD.

Az IPD megosztását támogató információ típusa

  • STUDY_PROTOCOL
  • NEDV

Gyógyszer- és eszközinformációk, tanulmányi dokumentumok

Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz

Igen

Egy amerikai FDA által szabályozott eszközterméket tanulmányoz

Nem

az Egyesült Államokban gyártott és onnan exportált termék

Igen

Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .

Iratkozz fel